Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 113Leukemia 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Lymphoma, Non-Hodgkin 59Multiple Myeloma 56Leukemia, Myeloid, Acute 56Lymphoma, Large B-Cell, Diffuse 55Hodgkin Disease 48Myelodysplastic Syndromes 43Burkitt Lymphoma 43Lymphoma, Follicular 41Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Mantle-Cell 40Breast Neoplasms 35Lymphoma, Large-Cell, Immunoblastic 34Sarcoma 27Neoplasms, Plasma Cell 27Central Nervous System Neoplasms 25Lymphoma, B-Cell, Marginal Zone 24Dendritic Cell Sarcoma, Interdigitating 19Recurrence 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 16Neuroblastoma 16Myeloproliferative Disorders 16Leukemia, Myeloid, Chronic-Phase 16Leukemia, Myeloid, Accelerated Phase 15Congenital Abnormalities 15Neutropenia 13Lung Neoplasms 13

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × Filgrastim × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡